Abstract P5-02-27: Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients
Lists
Only you see this
Abstract
Abstract Raised awareness of the importance of early diagnostics in breast cancer is leading to an increased incidence of ductal carcinoma in situ (DCIS) being detected through mammographic screening. DCIS is widely defined as a ‘Stage 0’ carcinoma with neoplastic cells still confined to the basement membrane. However, while most DCIS patients will receive widespread overtreatment for their carcinoma, the 20-year breast cancer mortality rate following a DCIS diagnosis, with or without treatment, remains at 3.3%. To better understand breast cancer carcinogenesis, recent studies have drawn attention to the clonal diversity within the DCIS tumor microenvironment and the presence of disseminated tumor cells in DCIS patients. However, there still exist gaps in understanding of characteristics at the time of diagnosis that make certain DCIS patients more likely to progress or recur. Ultimately, the goal of the project is to better inform DCIS patient risk stratification via the high throughput isolation and analysis of circulating biomarkers. In this study, we establish a workflow that targets the gaps in traditional tissue-based diagnostics by pivoting towards liquid biopsies. Our study not only builds on emerging literature on the early dissemination of breast cancer cells during carcinogenesis, but also investigates the value of circulating tumor cells (CTCs) as a biomarker in DCIS. To achieve a more holistic understanding of a patient’s carcinoma, we supplement our study with the Mouse INtraDuctal (MIND) models - an animal model that recapitulates the tumor microenvironment of DCIS in the mammary ducts of mice. We employed a high throughput, label-free microfluidic platform to enrich CTCs from DCIS patient samples. CTCs isolated from the unbiased platform were processed for single cell RNA sequencing along with white blood cells, red blood cells, and platelets that enabled further investigation of the circulating microenvironment and potential inter-cellular interactions. Further, to correlate findings in patient samples to an animal model wherein the timeline of progression to invasive disease can be shortened to 9 to 12 months (vs. 10+ years in patients), we analyzed blood samples from three different MIND models in a time course study over 12 months. Applying our workflow to 26 patient samples and 10 healthy controls, we identified CTCs in 96% of the patient samples. The average concentration of CTCs per mL of blood across all DCIS patients was significantly greater than that in the healthy controls (p < 0.0001, Mann-Whitney U Test). Through single cell RNA sequencing, inferred CNVs were found in two cell clusters that also encapsulated potential CTCs based on presence of canonical epithelial cell markers but absence of white blood cell genes. An epithelial to mesenchymal cell phenotype score was calculated (scale 0 to 100, respectively) for each potential CTC, and it was found that the median score tended around 50 to 60, supporting expanding literature on the hybrid epithelial-to-mesenchymal state of CTCs. In addition, during the MIND model time course study, CTCs were found in circulation as early as 3 months after formation of the models and while the models were still pre-invasive. Overall, our study enables the assessment of CTCs as a prognostic biomarker for DCIS patients. By studying CTCs in patient samples and their derived MIND models in parallel, we aim to continue to build an understanding of the drivers behind early dissemination. Further experimentation is also being planned to study the original tumor at a single cell level in comparison to the blood sequencing that has already been performed. The overarching goal is to compose a more holistic understanding of the origin of these malignant cells in circulation. Ultimately, we hope to investigate the value of CTCs as a clinical biomarker to inform personalized risk stratification for DCIS patients. Citation Format: Neha Nagpal, Brittany Rupp, Yan Hong, Fariba Behbod, Max Wicha, Sunitha Nagrath. Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-02-27.
BibTeX
@inproceedings{nagpal2025abstract,
author = {Neha Nagpal and Brittany Rupp and Hong Yan and Fariba Behbod and Max S. Wicha and Sunitha Nagrath},
title = {{Abstract P5-02-27: Investigating the Prognostic Significance of Circulating Tumor Cells in Ductal Carcinoma In Situ Patients}},
booktitle = {Clinical},
year = {2025},
doi = {10.1158/1557-3265.sabcs24-p5-02-27},
}Loading related content...